The vaccine against COVID-19 being developed and tested by Novavax has been accepted for rolling review by the European Medicines Agency (EMA). The vaccine, NVX-CoV2372, is in Phase 3 clinical trials ...

NEW YORK -- The American biotechnology company Novavax announced on Monday that its coronavirus vaccine candidate was found to have an overall efficacy of 90.4% in a Phase 3 trial conducted across the ...

(Reuters) - Top executives at U.S. pharmaceutical company Novavax Inc aren't waiting to see how well their COVID-19 vaccine works before they reap the financial rewards. Chief Executive Stanley Erck ...

CNN — Novavax on Monday announced the start of the Phase 3 trial of its Covid-19 vaccine in the United States and Mexico. It is the fifth company to launch a large-scale trial of a coronavirus vaccine ...

Novavax aims to convert emergency authorization to full approval FDA's request boosts Novavax shares by 18% Analysts confident in Novavax's approval despite past hurdles April 23 (Reuters) - Novavax ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Novavax benefited from this deal, but moving forward, there is far too much uncertainty surrounding it. For one, demand for coronavirus vaccines might no longer be what it once was. That's on top of ...

Novavax Inc. NVAX stock is trading higher on Friday in reaction to a surge in Moderna Inc. MRNA. Bloomberg noted that Moderna said it is conducting early-stage research into vaccines targeting ...